Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.

Emerging data indicates that Tarlatamab, a DLL3-targeted therapy, has inferior performance in small cell lung cancer (SCLC) that transformed from EGFR-mutant NSCLC compared to its efficacy in de novo SCLC. This suggests the biological context of transformation impacts treatment response, a critical nuance for this new therapy.

Unlike traditional cytotoxic agents, the DLL3-targeting T-cell engager tarlatumab demonstrates consistent overall survival benefits in third-line SCLC regardless of the patient's chemotherapy-free interval from first-line therapy. This indicates it works via a distinct mechanism that bypasses conventional chemoresistance pathways, representing a new treatment paradigm.

Drugs like cervatimig are engineered for improved safety. They feature a silenced Fc portion to prevent prolonged toxicity and a low-affinity CD3 binder that engages T-cells more physiologically. This design reduces the likelihood of high-grade cytokine release syndrome (CRS) and neurotoxicity.

Beyond efficacy, new therapies like bispecifics require significant institutional support. Clinicians need training for unfamiliar side effects like CRS, and facilities need resources like observation units and admission protocols, creating a steep implementation curve for clinical practice.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

Unlike novel challenges from bispecifics, upcoming SCLC therapies like antibody-drug conjugates (ADCs) and radiopharmaceuticals will benefit from existing familiarity. Community practices are already comfortable with these drug classes from their use in breast cancer (ADCs) and prostate cancer (radioligands), which should streamline their integration.

Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.

Adopting T-DXd in early-stage breast cancer requires frequent chest CT scans to monitor for potentially fatal interstitial lung disease (ILD), a practice not standard for current therapies. This presents significant new logistical challenges, including securing insurance approvals, managing patient access, and increasing the overall burden of care.